Post-Approval Studies Of Novartis’ TOBI Podhaler May Focus On Long-Term Efficacy
Executive Summary
Novartis’ TOBI Podhaler, intended to manage cystic fibrosis patients infected with Pseudomonas aeruginosa, passed FDA’s Anti-Infective Drugs Advisory Committee on an overwhelming vote, but lingering concerns remained.